- Hologic Inc HOLX has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe.
- The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen's genetic material causing COVID-19.
- The test runs on the fully automated Panther system.
- Hologic has expanded its manufacturing capability to produce Aptima tests in large quantities and has shipped more than 100 million Aptima COVID-19 tests globally since the spring of 2020.
- Approximately 2,600 Panther systems have been installed in clinical diagnostic laboratories around the world.
- Price Action: HOLX shares closed at $68.65 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
